End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.85 CNY | +2.27% | +6.90% | -17.82% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.82% | 592M | - | ||
+13.37% | 128B | A- | ||
-8.56% | 10.65B | A- | ||
+0.91% | 8.82B | C | ||
+18.59% | 7.19B | C | ||
+23.76% | 4.99B | B+ | ||
+7.25% | 3.4B | C- | ||
+0.09% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300653 Stock
- Ratings Yantai Zhenghai Biotechnology Co., Ltd.